This was a low-key week for the biotech sector before the onset of the first-quarter earnings season. Biotech giant Bristol Myers Squibb BMY was down on data from the schizophrenia study while ...

older antipsychotics offer once-daily dosing or even less frequent dosing schedules. After initially projecting Cobenfy could achieve $5.5 billion in revenue in 2030, Leerink has slashed that ...

The drug, Cobenfy, was approved last year based on data from three randomized studies comparing the drug to placebo. It was the first new mechanism-of-action approved for schizophrenia in decades.

On the heels of a clinical setback for Bristol Myers Squibb’s schizophrenia newcomer Cobenfy, the New Jersey pharma is serving up mixed results for the first three months of the year.

ARISE trial showed a 2-point PANSS reduction with Cobenfy adjunctive therapy, but it missed statistical significance (P = 0.11). FDA approved Cobenfy in Sept. 2024; global schizophrenia sales ...

p-value is nominal, not adjusted for multiplicity Cobenfy’s safety and tolerability profile as an adjunctive treatment was consistent with previous monotherapy trials. Further analysis will ...

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of exclusivity, has hit a phase 3 setback. Cobenfy as an adjunctive ...

Adjunctive use of xanomeline/trospium chloride (Cobenfy) offered no statistically significant benefit over placebo in adults with symptoms of schizophrenia inadequately controlled by an atypical ...

April 22 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab said on Tuesday its drug Cobenfy failed to show a statistically significant difference in a keenly watched late-stage trial that ...

Treatment with Cobenfy as an adjunctive demonstrated a ... seeking addition of extended dosing intervals (up to every 24 weeks) for Eylea HD (aflibercept) Injection 8 mg across all approved ...